A recent study suggests a potential link between Ozempic and vision loss, particularly non-arteritic anterior ischemic optic ...

Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug ...

Oral GLP-1 formulations represent a groundbreaking advance in obesity treatment, offering improved patient comfort and ...

A weekly diabetes medication may replace painful daily hormone injections for patients with congenital generalised lipodystrophy (CGL). Early findings suggest that tirzepatide – used for diabetes and ...

Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...

Opens in a new tab or window We have very little data right now to answer the question of whether we should be using a GLP-1 or GLP agonist and incretin mimetic during or even after cancer therapy.

New drugs are being developed to control blood glucose levels. For example, exenatide, an incretin mimetic agent, improves glucose control by mimicking the effects of glucagon-like peptide-1 ...

1 In this article, we explore the impact of incretin-mimetic drugs on muscle health and what can be done to limit these severe side effects. Incretins are intestinal hormones secreted in response to ...